[Ip-health] NIH: Prospective Grant of Exclusive License: Small Molecule Therapeutics Against Hepatitis C Virus Infection

Jamie Love james.love at keionline.org
Mon Mar 30 03:32:12 PDT 2015


The Federal Register: The Daily Journal of the United States Government
Prospective Grant of Exclusive License: Small Molecule Therapeutics Against
Hepatitis C Virus Infection
A Notice by the National Institutes of Health on 03/27/2015

Friday, March 27, 2015
Department of Health and Human Services
National Institutes of Health


Only written comments and/or applications for a license which are received
by the NIH Office of Technology Transfer on or before April 13, 2015 will
be considered.
Comments Close: 04/13/2015

Document Citation:
80 FR 16389
Page: 16389 -16390 (2 pages)
Document Number: 2015-06974
Shorter URL: https://federalregister.gov/a/2015-06974
ACTION

Notice.
SUMMARY

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that
the National Institutes of Health, Department of Health and Human Services,
is contemplating the grant of a start-up exclusive commercial patent
license agreement to practice the inventions embodied in U.S. provisional
patent application no. 61/909,414 (NIH Ref. No. E-011-2014/0-US-01) filed
November 27, 2013; International PCT application no. PCT/US2014/066680 (NIH
Ref. No. E-011-2014/0-PCT-02) filed November 20, 2014; Taiwanese patent
application no. 103141004 (NIH Ref. No. E-011-2014/0-TW-03) filed November
26, 2014; and U.S. provisional patent application no. 62/011,462 (NIH Ref.
No. E-161-2014/0-US-01) filed June 12, 2014; all entitled, “Heterocyclic
Compounds and Methods of Use Thereof;” and all continuing applications and
foreign counterparts to Virotas Biopharmaceuticals, LLC, a company having a
place of business in California. The patent rights in these inventions have
(a) been assigned to the United States of America, as represented by the
Secretary, Department of Health and Human Services who has delegated
authority for the licensing of inventions to the National Institutes of
Health or (b) been exclusively licensed to the National Institutes of
Health.

The prospective exclusive license territory may be “worldwide”, and the
field of use may be limited to the following: “Prevention and treatment of
Hepatitis C Virus infection.”

SUPPLEMENTARY INFORMATION:

Only written comments and/or applications for a license which are received
by the NIH Office of Technology Transfer on or before April 13, 2015 will
be considered.

Requests for copies of the patent application, inquiries, comments, and
other materials relating to the contemplated exclusive license should be
directed to: Kevin W. Chang, Ph.D., Senior Licensing and Patenting Manager,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301)
435-5018; Facsimile: (301) 402-0220; Email: changke at mail.nih.gov.

SUPPLEMENTARY INFORMATION:

The subject technologies are small molecule compounds for the treatment of
HCV infection identified using a novel cell-based high throughput assay.
Some of these compounds are derivatives of chlorcyclizine that show potent
antiviral properties against HCV. Chlorcyclizine is already on the market
for the treatment of allergic reactions, have been used extensively in
humans, and have excellent safety profiles with known pharmaceutical
properties. The other compounds are also heterocyclic compounds that show
anti-HCV activity. The subject technologies can potentially be used in
combination with each other and/or with other HCV therapeutics.
The prospective start-up exclusive commercial patent license will be
royalty bearing and will comply with the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The prospective start-up exclusive commercial
patent license may be granted unless within fifteen (15) days from the date
of this published notice, the NIH receives written evidence and argument
that establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Applications for a license in the field of use filed in response to this
notice will be treated as objections to the grant of the contemplated
exclusive license. Comments and objections submitted to this notice will
not be made availablefor public inspection and, to the extent permitted by
law, will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: March 23, 2015.

Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.

[FR Doc. 2015-06974 Filed 3-26-15; 8:45 am]

BILLING CODE 4140-01-P


-- 
James Love.  Knowledge Ecology International
http://www.keionline.org/donate.html
KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
+41.76.413.6584, twitter.com/jamie_love



More information about the Ip-health mailing list